MRK
Merck
October 14, 2026 · intraday
- Rarity
- 1.21
- Peak move
- +4.15%
- Float cap
- $350.6B
Merck is a research-intensive biopharmaceutical company that discovers, develops and markets prescription medicines, biologic therapies and vaccines, with its largest franchise in oncology led by Keytruda, alongside cardiometabolic, respiratory, infectious disease and diabetes products. It sells to drug wholesalers, retailers, hospitals, government agencies and managed care providers. A separate animal health business supplies veterinary pharmaceuticals and vaccines to veterinarians, distributors and livestock producers.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
10 events · 0 from SEC or newswire · 0 timed with the moveinstitutional_flowFirst Citizens Bank & Trust Co. increased its Merck stake by 16.1% in the third quarter, to 74,394 shares worth about $10.81 million.
board_changeMerck appointed Paul J. Diaz, managing partner at Cressey & Company and former CEO of Myriad Genetics and Kindred Healthcare, to its board effective Nov. 1, 2026, expanding the board to 14 members; he will serve on the Audit and Research committees and stand for shareholder election in May 2027.
- Key event
clinical_readoutMerck will present first-time pivotal Phase 3 results from its oncology pipeline at ESMO 2026 in Madrid (Oct. 23-27), including intismeran autogene plus KEYTRUDA in melanoma, sacituzumab tirumotecan in endometrial cancer, and KEYTRUDA in dMMR endometrial cancer, across 90+ abstracts.
- Key event
analyst_ratingCiti raised its price target on Merck to $145 from $125 while maintaining a Neutral rating, citing a constructive biopharma backdrop into Q3 earnings on volume growth and reduced policy concerns.
- Key event
patent_cliffFormycon and partner Zydus Lifesciences said the FDA accepted for review their BLA for FYB206, a biosimilar of Merck's Keytruda, with a decision possible in Q3 2027.
clinical_readoutFull BRUNELLO Phase 2b/3 data showed Merck's remigromig met the primary endpoint of non-inferiority versus ranibizumab in diabetic macular edema, with BCVA gains of 9.1 and 8.7 letters versus 11.8 and higher proliferative diabetic retinopathy events (6.7%/6.1% vs 0.9%).
analyst_ratingJefferies cut its risk-weighted peak sales estimate for Merck's remigromig by 60% to about $300 million from roughly $750 million and lowered its price target to $176 from $177 while keeping a Buy rating.
analyst_ratingRBC Capital lowered its price target on Merck to $145 from $150 while reiterating a Sector Perform rating.
analyst_ratingCantor Fitzgerald raised its price target on Merck to $145 from $120 while keeping a Neutral rating.
patent_eventA Dutch court found Merck's subcutaneous Keytruda infringes Halozyme's MDASE patent and ordered a halt to its manufacture and sale in eight European countries; Merck disputes the verdict and is reviewing its options.